Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791778 · ClinicalTrials.gov registry record · Phase 2
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
A Phase 2 study of Ovarian Neoplasms, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
- 20
- Study locations
NCT00791778 is a Phase 2 study of Ovarian Neoplasms that has completed, run by Bayer. The registered enrollment target is 246 participants, below the 361-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (32% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT00791778, a Phase 2 study of Ovarian Neoplasms, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
- 20
- Study locations
Study Summary
Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Sorafenib (Nexavar, BAY43-9006)
Study Locations (20)
Other
- - Bruxelles - Brussel
- - Bruxelles - Brussel
- - Edegem
- - La Louvière
- - Leuven
- - Wilrijk
- - Jyväskylä
- - Kuopio
- - Angers
- - Caen
- - Lyon
- - Tours
Ontario
- - Hamilton
- - London
- - Toronto
California
- - La Jolla
Florida
- - Jacksonville
Georgia
- - Augusta
Maine
- - Scarborough
Quebec
- - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791778
The ClinicalTrials.gov registry entry for NCT00791778 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 246 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 361-participant average among 38 other Ovarian Neoplasms trials with a reported enrollment target (32% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ovarian Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00791778 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT00791778 about?
NCT00791778 is a clinical study titled "Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer". Comparison of Nexavar with a placebo as maintenance therapy for patients with advanced Ovarian or primary Peritoneal cancers in complete remission following surgery and one regimen of chemotherapy.
What is the current status of trial NCT00791778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2008-11. Estimated completion is 2012-12.
What conditions does trial NCT00791778 study?
This clinical trial studies the following conditions: Ovarian Neoplasms.
What interventions are being tested in trial NCT00791778?
The interventions under investigation include: Placebo (DRUG), Sorafenib (Nexavar, BAY43-9006) (DRUG).
Who is sponsoring clinical trial NCT00791778?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00791778 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Maine, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
RECRUITING · Phase 2
-
Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Trial of Vigil for Participants With Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens
COMPLETED · Phase 2
-
AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.